Plasmodium spp. parasites that cause malaria disease remain a significant global-health
burden. With the spread of parasites resistant to artemisinin combination therapies in …

ABSTRACT Introduction The deployment of Artemisinin-based combination therapies and
transmission control measures led to a decrease in the global malaria burden over the …

Calcium signaling regulated by the cGMP-dependent protein kinase (PKG) controls key life
cycle transitions in the malaria parasite. However, how calcium is mobilized from …

Protein and phosphoinositide kinases have been successfully exploited as drug targets in
various disease areas, principally in oncology. In malaria, several protein kinases are under …

In malaria parasites, evolution of parasitism has been linked to functional optimisation.
Despite this optimisation, most members of a calcium-dependent protein kinase (CDPK) …

Antimalarial drug resistance compels the quest for new compounds that target alternative
pathways to current drugs. The Plasmodium cyclic GMP-dependent protein kinase (PKG) …

Humans have lived in tenuous battle with malaria over millennia. Today, while much of the
world is free of the disease, areas of South America, Asia, and Africa still wage this war with …

Over 20 years after the approval of the first-in-class protein kinase inhibitor imatinib, the
biological function of a significant fraction of the human kinome remains poorly understood …

Abstract Imidazo [1, 2-b] pyridazine scaffold represents an important class of heterocyclic
nucleus which provides various bioactives molecules. Among them, the successful kinase …

Advances in the genetics, function, and stage-specificity of Plasmodium kinases has driven
robust efforts to identify targets for the design of antimalarial therapies. Reverse genomics …